Trans-activating mutations of the pseudokinase ERBB3.

Autor: Koivu MKA; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, 20520, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, 20520, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, 20520, Finland., Chakroborty D; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, 20520, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, 20520, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, 20520, Finland., Airenne TT; Structural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520, Turku, Finland., Johnson MS; Structural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520, Turku, Finland., Kurppa KJ; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, 20520, Finland., Elenius K; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, 20520, Finland. klaele@utu.fi.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, 20520, Finland. klaele@utu.fi.; Department of Oncology, Turku University Hospital, Turku, 20521, Finland. klaele@utu.fi.

Publikováno v: Oncogene [Oncogene] 2024 Jul; Vol. 43 (29), pp. 2253-2265. Date of Electronic Publication: 2024 May 28.

Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases.

Autor: Koivu MKA; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Chakroborty D; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Tamirat MZ; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland., Johnson MS; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland., Kurppa KJ; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, Finland., Elenius K; Institute of Biomedicine, and Medicity Research Laboratories, University of Turku, Turku, Finland. klaus.elenius@utu.fi.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Department of Oncology, Turku University Hospital, Turku, Finland.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar; Vol. 20 (3), pp. 564-576. Date of Electronic Publication: 2020 Dec 15.

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.

Autor: Momeny, Majid, Tienhaara, Mari, Sharma, Mukund, Chakroborty, Deepankar, Varjus, Roosa, Takala, Iina, Merisaari, Joni, Padzik, Artur, Vogt, Andreas, Paatero, Ilkka, Elenius, Klaus, Laajala, Teemu D, Kurppa, Kari J, Westermarck, Jukka

Publikováno v: EMBO Molecular Medicine; Jul2024, Vol. 16 Issue 7, p1603-1629, 27p